NEW YORK (GenomeWeb News) – Evogene today reported a 31 percent revenue spike for the third quarter ended Sept. 30.
The Rehovot, Israel-based plant genomics firm reported total revenues of $3.4 million for the quarter compared to $2.6 million for the third quarter of 2010.
Evogene's net loss for the quarter was $2.3 million, or $.07 per share, versus a loss of $3.6 million, or $.12 per share, for the third quarter of 2010.
Its R&D spending jumped 33 percent to $2 million from $1.5 million, while its business development, general, and administrative costs declined slightly to $767,000 from $780,000 year over year.
Evogene finished the quarter with around $60 million in cash, cash equivalents, marketable securities, and short-term deposits.